Fig. 2From: Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programmeRate of change in FVC over 12 weeks in the INMARK and INPULSIS trials. a [43],; b [2, 41], and data on file (Boehringer Ingelheim). CI, confidence interval; FVC, forced vital capacity; SE, standard errorBack to article page